This renewal application is focused on understand the molecular mechanisms of hepatic innate immunity that controls the outcome of hepatitis C virus (HCV) infection. We have shown that retinoic acid inducible gene-I (RIG-I) initiates the hepatic innate immune response upon recognition and binding of the pathogen associated molecular pattern (PAMP) consisting of 5'triphosphate with poly-uridine (poly-U/UC) within the HCV RNA. During acute infection this recognition of transmission/founder (T/F) viral genome by RIG-I results in its modification and activation to bind the MAVS adaptor protein on mitochondria-associated membranes (MAM) and signal hepatic innate immune defenses that restrict infection. Our preliminary studies now reveal that T/F genomes from patients exhibit remarkable variation within their poly-U/UC motif, and that this variation imparts differential recognition and binding by RIG-I that allows escape from non-self recognition. Moreover, we have found that signaling by RIG-I is dependent on formation of a RIG-I translocon protein complex to facilitates RIG-I cytosol-to-membrane translocation for MAVS interaction and signaling. Our studies now reveal that these activities are governed by the reversible acteylation of RIG-I, and that this process is likely controlled through the HDAC6 protein as a RIG-I cofactor of innate immunity. We show that HCV evades hepatic innate immunity via MAM targeting by the NS3/4A viral protease to cleave MAVS and disrupt RIG-I signaling, thereby facilitating chronic infection, and this action is dependent on stable NS3/4A-MAVS interaction on the MAM. Ablation of this interaction restores innate immunity to prevent acute to chronic HCV transition. We hypothesize that regulation of the RIG-I pathway and hepatic innate immunity are major determinants controlling the acute to chronic transition of HCV infection. We will therefore conduct studies to: 1) Define the features of RIG-I and the HCV poly-U/UC motif that confer PAMP binding and innate immune signaling activation, and determine how PAMP variation among T/F genomes influences acute innate immune induction by HCV;2) Determine the role of reversible acetylation in RIG-I translocon assembly and function;3. Identify the cognate/reciprocal motifs of NS3/4A and MAVS that mediate interaction and control of the RIG-I pathway.
Liver disease from microbial infection is a major public health concern. Hepatitis C virus (HCV) infects the liver to cause liver disease, liver cancer, and death. Our studies will define the virus and host components that control HCV infection outcome and liver disease.
|Pattabhi, Sowmya; Wilkins, Courtney R; Dong, Ran et al. (2016) Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol 90:2372-87|
|Hong, MeeAe; Schwerk, Johannes; Lim, Chrissie et al. (2016) Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med 213:2539-2552|
|Altfeld, Marcus; Gale Jr, Michael (2015) Innate immunity against HIV-1 infection. Nat Immunol 16:554-62|
|Kell, Alison M; Gale Jr, Michael (2015) RIG-I in RNA virus recognition. Virology 479-480:110-21|
|McFarland, Adelle P; Horner, Stacy M; Jarret, Abigail et al. (2014) The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 15:72-9|
|Horner, Stacy M; Gale Jr, Michael (2013) Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19:879-88|
|Negash, Amina A; Ramos, Hilario J; Crochet, Nanette et al. (2013) IL-1Î² production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 9:e1003330|
|Ireton, ReneÃ© C; Gale Jr, Michael (2013) Systems biology analyses to define host responses to HCV infection and therapy. Curr Top Microbiol Immunol 363:143-67|
|Lau, Daryl T-Y; Negash, Amina; Chen, Jie et al. (2013) Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144:402-413.e12|
|Wilkins, Courtney; Woodward, Jessica; Lau, Daryl T-Y et al. (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461-9|
Showing the most recent 10 out of 15 publications